Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1984 Dec;18(3):174–178. doi: 10.1007/BF00205508

Purified mouse mammary tumor and lymphoid cells in immune assays

Beverly A Blazar 1,, Farkas Vanky 1, Eva Klein 1
PMCID: PMC11039195  PMID: 6568874

Abstract

Tumor and lymphoid cell components from primary mammary adenocarcinomas of C3H/He mice were isolated simultaneously by velocity gradients. Viable tumor cells were obtained in sufficient numbers to test their in vivo and in vitro growth. Isolated tumor cells grew in 97% of inoculated syngeneic animals. In six assays with different tumors the effects of tumor-associated lymphoid cells (TAL) on in vivo tumor growth varied, enhancing in three and delaying in two experiments. Isolated tumor cells from animals with enhancing TAL grew faster in nonirradiated mice, whereas tumor cells from animals with inhibitory TAL grew better in irradiated animals. Isolated tumor cells also proliferated in cell culture, where they averaged 35% primary plating efficiency. Separated tumor cells were used in short-term 51Cr-release assays with TAL, tumor-bearer lymph node and spleen effectors. Cytotoxicity was detected in only five of 25 assays. In no case was there killing by lymphocyte populations from normal animals. In the present report we describe a technique for the isolation of viable tumor and lymphoid cells from murine adenocarcinomas that allows study of interactions between these populations from the original tumor-bearing host.

Keywords: Adenocarcinoma, Velocity Gradient, Mammary Tumor, Lymphoid Cell, Viable Tumor

Footnotes

Postdoctoral fellow of the Fogarty International Foundation. Present address: Department of Surgery, Harvard Medical School and Brigham & Women's Hospital, Boston, MA 02215, USA

References

  • 1.Blazar BA, Heppner GH. In situ lymphoid cells of mouse mammary tumors. I. Development and evaluation of a method for the separation of lymphoid cells from mouse mammary tumors. J Immunol. 1978;120:1876. [PubMed] [Google Scholar]
  • 2.Blazar BA, Heppner GH. In situ lymphoid cells of mouse mammary tumors. II. The characterization of lymphoid cells separated from mouse mammary tumors. J Immunol. 1978;120:1881. [PubMed] [Google Scholar]
  • 3.Blazar BA, Miller FR, Heppner GH. In situ lymphoid cells of mouse mammary tumors. III. In vitro stimulation of tumor cell survival by lymphoid cells separated from mammary tumors. J Immunol. 1978;120:1887. [PubMed] [Google Scholar]
  • 4.Blazar BA, Laing CA, Miller FR, Heppner GH. Activity of lymphoid cells separated from mammary tumors in blastogenesis and Winn assays. JNCI. 1980;65:405. [PubMed] [Google Scholar]
  • 5.Blazar BA, Galili N, Klein E. Effects of isolated tumor lymphocytes alone and with adherent cells. Cancer Immunol Immunother. 1984;18:179. doi: 10.1007/BF00205509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dexter D, Kowalski HM, Blazar BA, Fliegel Z, Vogel R, Heppner GH. Heterogeneity of tumor cells from a single mammary tumor. Cancer Res. 1978;38:3174. [PubMed] [Google Scholar]
  • 7.Dunn T. Morphology of mammary tumors in mice. In: Homburger F, Fishman NH, editors. Pathophysiology of cancer. 2nd edn. New York: Hoeber; 1959. p. 38. [Google Scholar]
  • 8.Fidler IJ, Kripke ML. Metastasis results from pre-existing variant cells within malignant tumor. Science. 1977;197:893. doi: 10.1126/science.887927. [DOI] [PubMed] [Google Scholar]
  • 9.Galili N, Devens B, Noor D, Becker S, Klein E. Immune responses to weakly immunogenic virally induced tumors. 1. Overcoming low responsiveness by priming mice with a syngeneic in vitro tumor or allogeneic cross reactive tumor. Eur J Immunol. 1978;8:17. doi: 10.1002/eji.1830080105. [DOI] [PubMed] [Google Scholar]
  • 10.Haskill JS, Hayry P, Radov LA. Systemic and local immunity in allograft and cancer infection. Contemp Top Immunobiol. 1978;8:107. doi: 10.1007/978-1-4684-0922-2_5. [DOI] [PubMed] [Google Scholar]
  • 11.Klein E, Vanky F. Natural and activated cytotoxic lymphocytes which act on autologous and allogeneic tumor cells. Cancer Immunol Immunother. 1981;11:111. [Google Scholar]
  • 12.Klein E, Vanky F, Galili U, Vose BM, Fopp M. Separation and characteristics of tumor-infiltrating lymphocytes in man. Contemp Top Immunobiol. 1980;10:79. doi: 10.1007/978-1-4684-3677-8_4. [DOI] [PubMed] [Google Scholar]
  • 13.Nowell PG. The clonal evolution of tumor cell populations. Science. 1976;194:23. doi: 10.1126/science.959840. [DOI] [PubMed] [Google Scholar]
  • 14.Prehn RT. Analysis of antigenic heterogeneity with individual 3-methylcholanthrene-induced mouse sarcomas. J Natl Cancer Inst. 1970;45:1039. [PubMed] [Google Scholar]
  • 15.Pretlow TG. Estimation of experimental conditions that permit cell separations by velocity sedimentation as isokinetic gradients of Ficoll in tissue culture medium. Anal Biochem. 1971;41:248. doi: 10.1016/0003-2697(71)90207-7. [DOI] [PubMed] [Google Scholar]
  • 16.Rios AM, Miller FR, Heppner GH. Characterization of tumor-associated lymphocytes in a series of mouse mammary tumor line with differing biological properties. Cancer Immunol Immunother. 1983;15:83. doi: 10.1007/BF00199696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vose BN, Vanky F, Klein E. Lymphocyte cytotoxicity against autologous tumor biopsy cells in humans. Int J Cancer. 1977;20:512. doi: 10.1002/ijc.2910200407. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES